Abemaciclib and Letrozole to Treat Endometrial Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II single arm trial to determine the percentage of patients without evidence
of disease progression on abemaciclib and letrozole in advanced stage, persistent or
recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either
unacceptable toxicity, progression of disease, or investigator/patient request for
withdrawal.